-
Founded in:
1993-12-31 -
Country:
China -
Address:
No. 2158 Huangpujiang Middle Road, Kunshan Development Zone, Jiangsu Province -
Tax NO.:
91320583608278334C -
Registered Funds:
$25,416,780 -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cetirizine dihydrochloride |
Antihistamine effect
More
Antihistamine effect |
83881-52-1 | 54 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| [4-Chlorobenzoyl-beta;-aminoethylphenoxy]isobutyric acid |
This product is a lipid-regulating drug of the clofibric acid derivative class. It has two mechanisms for lowering blood lipids. First, this product increases the activity of lipoprotein lipase and liver lipase, promotes the catabolism of very low-density lipoprotein, and reduces the level of blood triglycerides. Secondly, this product reduces the secretion of very low-density lipoprotein. This product reduces blood low-density lipoprotein and cholesterol, possibly by enhancing the clearance of receptor-bound low-density lipoprotein. This product has a stronger effect on lowering blood triglycerides than lowering blood cholesterol, and also increases high-density lipoprotein. In addition, this product can also reduce blood fibrinogen. Existing studies have not found that this product has carcinogenic or mutagenic effects.
More
This product is a lipid-regulating drug of the clofibric acid derivative class. It has two mechanisms for lowering blood lipids. First, this product increases the activity of lipoprotein lipase and liver lipase, promotes the catabolism of very low-density lipoprotein, and reduces the level of blood triglycerides. Secondly, this product reduces the secretion of very low-density lipoprotein. This product reduces blood low-density lipoprotein and cholesterol, possibly by enhancing the clearance of receptor-bound low-density lipoprotein. This product has a stronger effect on lowering blood triglycerides than lowering blood cholesterol, and also increases high-density lipoprotein. In addition, this product can also reduce blood fibrinogen. Existing studies have not found that this product has carcinogenic or mutagenic effects. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cetirizine dihydrochloride |
This product is a selective histamine H1 receptor antagonist. Animal experiments show that this product has no obvious anticholinergic and anti-5-hydroxytryptamine effects, and is not easy to pass through the blood-cerebrospinal fluid barrier to act on the central H1 receptor. When used clinically, the central inhibitory effect is relatively mild.
More
This product is a selective histamine H1 receptor antagonist. Animal experiments show that this product has no obvious anticholinergic and anti-5-hydroxytryptamine effects, and is not easy to pass through the blood-cerebrospinal fluid barrier to act on the central H1 receptor. When used clinically, the central inhibitory effect is relatively mild. |
83881-52-1 | 54 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Liranaftate |
Extract from the above information
More
Extract from the above information |
88678-31-3 | 11 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ramiprilat |
No specific pharmacological effects mentioned
More
No specific pharmacological effects mentioned |
87269-97-4 | 15 |